Ambu account plan
Innovative single-use medical devices
At a glance
Danish maker of single-use endoscopes and anesthesia and patient-monitoring devices: DKK 6,471m revenue in FY2025/26, ~5,400 employees.
Ambu A/S, founded in 1937 and based in Ballerup near Copenhagen, develops, manufactures and sells medical devices and positions itself as the global leader in single-use endoscopy, with 60%+ share of the single-use market. It sells in 60+ markets, with North America at 50% of revenue and Europe at 40%, makes its products in four factories (Mexico, Malaysia, China, U.S.) and has ~5,400 employees. In FY2025/26 (to 30 September 2026) revenue was DKK 6,471m, organic growth 10.1%, EBIT DKK 851m (13.2% margin) and net profit DKK 642m. Its class B shares are listed on Nasdaq Copenhagen, while the Hesse founding family holds 17.3% of capital and 61.5% of votes through unlisted A shares.
Business units
Respiratory (Endoscopy Solutions)
32% of FY2025/26 revenue (DKK 2,031m)Single-use bronchoscopes (aScope 4 and aScope 5 Broncho) for the OR and ICU, plus the SureSight video laryngoscopy portfolio for airway management. Organic growth was 14.6% in FY2025/26 and 21% in Q4, as SureSight gained momentum and SureSight Mobile was cleared in the U.S. and UK; two aScope 5 bronchoscopes received pediatric indications.
Urology, ENT & GI (Endoscopy Solutions)
32% of FY2025/26 revenue (DKK 2,095m)Single-use cystoscopes and ureteroscopes, rhinolaryngoscopes and GI endoscopes, plus the newly acquired TIMS Medical ENT software. Organic growth was 18.2% in FY2025/26, driven by cystoscopy and rhinolaryngoscopy as procedures move to outpatient and ambulatory surgery centers; ureteroscopy share gains are slower than planned in a crowded market.
Anesthesia (Anesthesia & Patient Monitoring)
18% of FY2025/26 revenue (DKK 1,188m)Airway management and anesthesia consumables. Organic revenue fell 1.7% after volume losses in selected U.S. accounts under non-exclusive contracts that followed two years of price increases; Ambu expects a return to positive but muted growth in 2026/27.
Patient Monitoring (Anesthesia & Patient Monitoring)
18% of FY2025/26 revenue (DKK 1,157m)Electrodes for cardiology and neurology, with neurology performing strongly. Organic growth was 2.7% in FY2025/26; the Neuroline Cup MRI/CT EEG electrode received FDA clearance and CE mark, with commercialization starting in 2026/27.
Strategic priorities
- ZOOM AHEAD: global endoscopy leadership
- The 2030 strategy launched on 1 October 2025 targets 11-13% organic revenue CAGR to 2029/30 (Endoscopy Solutions 15-20%, A&PM 3-5%), an EBIT margin of 20%+ and cash conversion of 40%+.
- Converting endoscopy to single-use
- Single-use is only 3-4% of a DKK 190bn endoscopy opportunity, with penetration of 20% in Respiratory, 10% in Urology, 2-4% in ENT and below 1% in GI; Ambu plans to Win in Respiratory and Urology, Grow in ENT and Unlock GI.
- New endoscope generations in two years
- Over the next two financial years Ambu plans more than seven new solutions, including four new generations of endoscopes across Respiratory, Urology, ENT and GI, starting with an ENT rhinolaryngoscope.
- EndoIntelligence software, AI and EMR integration
- Ambu is extending its EndoIntelligence platform beyond hardware into software, AI, cybersecurity and hospital EMR connectivity, helped by the TIMS Medical acquisition and AI partnerships with U.S. medical institutions for bronchoscopy.
- Selling to hospital decision makers
- The U.S. commercial organization was rebuilt from April 2026 around hospitals and health-system decision makers, with separate Urology and ENT sales forces.
- Margin expansion through the OPEX ratio
- EBIT is to grow faster than revenue every year, with 80% of the margin expansion coming from the OPEX ratio (mainly administration and distribution costs), alongside standardization of Finance, Operations and R&D processes ahead of core-system upgrades.
Latest results
In Q4 2025/26 organic growth reached 13.9%, with Endoscopy Solutions at 21.2% and A&PM at 2.8%, and an EBIT margin of 17.2% that included DKK 85m of tariff refunds. For the full year FY2025/26, revenue rose to DKK 6,471m (DKK 6,037m) with 10.1% organic growth, the EBIT margin was 13.2% (13.0%) and FCF before acquisitions was DKK 487m (cash conversion 39%). Guidance for 2026/27 is organic growth of 9.5-11.5% (Endoscopy Solutions around 15%), an EBIT margin of 13-15% assuming a tariff expense of 1% of revenue and no refunds, and cash conversion of ~30% on higher capex ahead of the new endoscope launches.
Investments and deals
- Acquisition of TIMS Medical
- Acquired on 11 September 2026 for an enterprise value of USD 45m plus up to USD 20m earn-out: U.S. ENT imaging, reporting and documentation software with ~7,000 U.S. hospital installations, 56 employees and DKK ~97m of annual revenue.
- Mexico factory ramp-up
- Production is moving from Malaysia to Mexico to balance the footprint, mitigate tariffs and serve North America; the Mexico factory is above 50% utilization.
- Capex for launches and automation
- Investments in property, plant, equipment and right-of-use assets were DKK 314m in 2025/26 (DKK 185m); capex rises in 2026/27 for new production lines and manufacturing automation, and innovation spending is more than DKK 500 million.
- Shareholder returns
- DKK 559m was returned in 2025/26 (DKK 109m dividend, DKK 450m buybacks); for 2026/27 a DKK 151m dividend and a DKK 400m buyback are planned.
Challenges and risks
- Anesthesia volume losses in the U.S.
- A&PM grew only 0.4% organically in FY2025/26 after price increases cost volumes at selected U.S. accounts under non-exclusive contracts; the effect annualizes into 2026/27.
- Competition and pricing in Urology
- Ureteroscopy is a crowded single-use market where share gains are slower than planned, and strategic price initiatives against low-cost players in cystoscopy weighed on gross margin.
- Tariffs and currency
- Tariff expense was around DKK 160m (2.5% of revenue) in 2025/26, with an expected drag of about 1% of revenue in 2026/27; about 51% of revenue is invoiced in USD, which management calls the biggest external factor.
- Supply, quality and cybersecurity risk
- The annual report names disruption at a manufacturing site or single-source supplier, quality processes and cybersecurity and IT resilience among its main risks; Ambu is dual sourcing critical components.
- Elevated working capital and lower cash conversion
- Net working capital was 23% of revenue at 30 September 2026, above the ~20% target on elevated inventory, and cash conversion is guided at ~30% for 2026/27, below the 40% target.
What leadership says
“We delivered another strong quarter, with 16% growth in Endoscopy Solutions and market share gains in all endoscopy areas, reinforcing Ambu's leadership in the conversion to single-use endoscopes.”
“over the next 2 financial years, so the next 24 months, we are going to launch new generations of endoscopes across our 4 main endoscopy areas”
“a very sticky point for customers. So once we are integrated, they stay with Ambu”
“cost inflation still is not a big theme internally in Ambu”
Where a supplier can help
- Hospital IT, EMR and AI integration
- The EndoIntelligence priority and the TIMS Medical acquisition call for EMR connectivity, cybersecurity, imaging software and AI partners, an area the CFO calls sticky for customers.
- Manufacturing automation and the Mexico ramp-up
- Higher capex for new production lines, manufacturing automation and the transfer of production from Malaysia to Mexico open room for automation, equipment and industrial service suppliers.
- Administration and distribution efficiency
- With 80% of planned margin expansion to come from the OPEX ratio and core-system upgrades ahead, suppliers of ERP, finance and logistics tools and process automation fit the margin priority.
- Selling to hospital decision makers
- The rebuilt U.S. commercial organization, targeting hospital administration and health-system decision makers with separate Urology and ENT sales forces, could use sales enablement, health-system data and CRM tools.
- Supply chain resilience
- Single-source supplier risk, dual sourcing of critical components and tariff exposure make component suppliers and trade compliance services relevant.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Ambu?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report 2025/26
- Ambu A/S (Ballerup, Denmark; class B shares on Nasdaq Copenhagen) calls itself the global leader in single-use endoscopy, with 60%+ share of the single-use market, ~5,400 employees, 4 factories (Mexico, Malaysia, China, U.S.) and 3 key R&D centers (Denmark, Germany, Malaysia), selling in 60+ markets.
- FY2025/26 (to 30 September 2026): revenue DKK 6,471m (DKK 6,037m), organic growth 10.1% (13.1%), reported growth 7.2%; EBIT DKK 851m, EBIT margin 13.2% (13.0%); net profit DKK 642m; FCF before acquisitions DKK 487m; cash conversion 39%.
- Two business areas: Endoscopy Solutions (64% of revenue, +16.4% organic, fourth straight year above 15%) and Anesthesia & Patient Monitoring (36%, +0.4%); North America is 50% of revenue (+11.0%), Europe 40% (+9.1%), Rest of World 10% (+9.6%).
- ZOOM AHEAD strategy (launched 1 October 2025) aims at "global endoscopy leadership"; 2029/30 targets: 11-13% organic revenue CAGR (Endoscopy Solutions 15-20%, A&PM 3-5%), EBIT margin 20%+, cash conversion 40%+. The interim target of ~20% EBIT margin in 2027/28 is replaced by earnings growing ahead of organic revenue each year.
- Market thesis: single-use is only 3-4% of a DKK 190bn endoscopy opportunity, growing 20%+ a year 2025-2030; penetration is 20% in Respiratory, 10% in Urology, 2-4% in ENT and below 1% in GI.
- Acquired TIMS Medical (U.S. ENT imaging, reporting and documentation software; ~7,000 U.S. hospital installations, 56 employees, DKK ~97m revenue) in September 2026 for USD 45m EV plus up to USD 20m earn-out, to extend the EndoIntelligence platform.
- Guidance 2026/27: organic growth 9.5-11.5% (Endoscopy Solutions ~15%, A&PM low single digit), EBIT margin 13-15% assuming a tariff expense of 1% of revenue and no refunds, cash conversion ~30% on higher capex ahead of new endoscope launches in all four endoscopy areas over the next two years.
- Shareholder returns: DKK 559m paid in 2025/26 (DKK 109m dividend, DKK 450m buybacks); DKK 551m planned for 2026/27 (DKK 151m proposed dividend, DKK 400m buyback). The Hesse founding family holds 17.3% of capital and 61.5% of votes through unlisted A shares.
- Main risks named: product supply and quality, cybersecurity, tariffs and geopolitics (tariff expense ~DKK 160m, 2.5% of revenue, in 2025/26; tariff refunds DKK 125m), legal/compliance, FX (about 51% of revenue invoiced in USD).
- Interim Report for Q3 2025/26
- Q3 2025/26 (April-June 2026): revenue DKK 1,640m (DKK 1,507m), organic growth 10.3% (12.0%), reported growth 8.8%.
- Endoscopy Solutions +16.0% organic and 64% of revenue: Respiratory +17.1% (SureSight Mobile launch), Urology, ENT & GI +15.0%.
- Anesthesia & Patient Monitoring +1.6% organic (36% of revenue): Anesthesia -0.4% after volume losses in selected U.S. non-exclusive accounts, Patient Monitoring +3.6%.
- Regions: North America +9.7%, Europe +10.2%, Rest of World +14.4%. Nine-month organic growth 8.7% on revenue of DKK 4,771m.
- EBIT DKK 221m, margin 13.5% (11.3%), helped by operating leverage and the first IEEPA tariff refunds, partly offset by investments in the commercial organization; FCF before acquisitions DKK 154m (DKK 128m).
- Full-year 2025/26 organic growth guidance cut to ~10% (from 10-12%) because A&PM now expected at very low single digit; EBIT margin guidance of 12-14% kept, "toward the high end"; Endoscopy Solutions +15% maintained.
- Business highlights: Neuroline Cup MRI/CT, 'best-in-class' cybersecurity validation for aView 2 Advance and aBox 2, AI partnerships with U.S. medical institutions for future bronchoscopy, continued Mexico ramp-up to manage tariffs.
- Capital returns: DKK 150m buyback completed in February 2026; a new buyback of up to DKK 300m running to 30 September 2026 (DKK 123.6m repurchased by 30 June).
- Ambu Q4 and full-year 2025/26 earnings call transcript
- CEO Britt Meelby Jensen and CFO Henrik Skak Bender presented Q4 and full-year 2025/26 on 5 November 2026: Q4 organic growth 13.9%, Endoscopy +21.2%, A&PM +2.8%; full year 10.1%, Endoscopy 16.4%, A&PM 0.4%.
- Q4 EBIT margin 17.2%, including DKK 85m of tariff refunds (about 5 percentage points) and ~DKK 20m of tariff cost; full-year FCF DKK 487m, cash conversion 39%.
- Innovation is the story for 2026/27: "more than seven new solutions", including four new generations of endoscopes across Respiratory, Urology, ENT and GI within two financial years, starting with an ENT rhinolaryngoscope; ramp-up expected to be gradual, with no "immediate hockey stick effect".
- TIMS Medical (closed 11 September, 56 staff, 7,000 mainly ENT installations) strengthens EndoIntelligence; TIMS-related transaction and integration costs of DKK 20-25 million over Q3-Q4 sit in OPEX.
- Guidance 2026/27: organic growth 9.5-11.5% (Endoscopy ~15%), EBIT margin 13-15% with a ~1 point tariff drag and no refunds included, cash conversion ~30% on higher capex for launches.
- 2029/30 targets kept (11-13% CAGR, 20%+ EBIT margin, 40%+ cash conversion); the mid-term ~20% EBIT margin is replaced by EBIT growing faster than revenue every year; 80% of the margin expansion is to come from the OPEX ratio.
- Urology: strong cystoscope volumes with selective "price concession" versus low-cost players; ureteroscopy share gains slower than planned. EMR integration is described as "a very sticky point for customers".
- Shareholder returns: proposed dividend DKK 151m (DKK 0.56 per share) and a DKK 400m buyback over six months; the Mexico factory is above 50% utilization.
- Ambu Q3 2025/26 earnings call transcript
- Q3 2025/26 call, 26 August 2026, with CEO Britt Meelby Jensen and CFO Henrik Skak Bender: Endoscopy +16%, Respiratory +17.1%, Urology, ENT & GI +15% (16.9% rolling 12 months), EBIT margin 13.5%, guidance trimmed to ~10% organic growth.
- Jensen: Respiratory growth comes mainly from conversion of reusable bronchoscopes, with SureSight creating "a new adjacency" and synergies with the aScope 4 and aScope 5 portfolio.
- Urology: Ambu leads cystoscopy (entered as first mover in 2020) but in ureteroscopy is "not gaining market share as fast as we expected" in "a much more crowded market"; new-generation solutions within two years are the answer.
- U.S. commercial setup reorganized from April 2026 around hospitals and decision makers, with separate Urology and ENT sales forces; the related hiring and onboarding costs are now at run rate.
- Bender: about DKK 40m of IEEPA tariff refunds received in Q3, a further DKK 85m after quarter end (booked in Q4) and another DKK 70m outstanding; underlying tariff cost runs at about 1 percentage point of margin.
- Adjusted EBIT margin 12.5% in Q3 (vs 15.2% and 14.5% in Q1 and Q2), held back by one-off strategic projects, sales-force ramp-up and USD/DKK.
- Pricing: selective "strategic pricing" in cystoscopy and ASCs, but Ambu is still "at a significant premium" to other single-use players; cost inflation "still is not a big theme internally".
- Mexico vs Malaysia: landed cost is at the same level excluding tariffs; FX is by far the biggest external factor.
Questions about Ambu
What does Ambu do?
Ambu develops, manufactures and sells medical devices, mainly single-use endoscopes for respiratory, urology, ENT and GI procedures, plus anesthesia and patient-monitoring products. It claims 60%+ share of the single-use endoscopy market.
What is Ambu's revenue?
Revenue was DKK 6,471m in FY2025/26 (to 30 September 2026), with 10.1% organic growth and an EBIT margin of 13.2%. Endoscopy Solutions made up 64% of revenue.
How many employees does Ambu have?
Ambu has ~5,400 employees across 20+ countries; the average number of employees in FY2025/26 was 5,569.
What is Ambu's strategy?
ZOOM AHEAD, launched in October 2025, aims at global endoscopy leadership by converting procedures to single-use endoscopes, with 2029/30 targets of 11-13% organic revenue CAGR and an EBIT margin of 20%+.
Who leads Ambu?
Britt Meelby Jensen is CEO (joined 2022) and Henrik Skak Bender is CFO (joined 2024); the board is chaired by Jørgen Falkebo Jensen.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)